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Arndt J. Schottelius1, Ulrich Zu¨gel2, Wolf-Dietrich Do¨cke3, Thomas M. Zollner3, Lars Ro¨se3, Anne Mengel4,
Bernd Buchmann4, Andreas Becker5, Gerald Gru¨tz6, Sandra Naundorf6, Anke Friedrich6, Matthias Gaestel7
and Khusru Asadullah3
Mitogen-activated protein kinase-activated protein kinase 2 (MK2) is a downstream molecule of p38, involved in
the production of TNF-a, a key cytokine, and an established drug target for many inflammatory diseases. We
investigated the role of MK2 in skin inflammation to determine its drug target potential. MK2 deficiency
significantly decreased plasma TNF-a levels after systemic endotoxin application. Deficient mice showed
decreased skin edema formation in chronic 2-O-tetradecanoylphorbol-13-acetate (TPA)-induced irritative
dermatitis and in subacute 2,4-dinitrofluorobenzene (DNFB)-induced contact hypersensitivity. Surprisingly, MK2
deficiency did not inhibit edema formation in subacute 2,4-dinitrochlorobenzene (DNCB)-induced contact
allergy and even increased TNF-a and IL-1b levels as well as granulocyte infiltration in diseased ears. Ear
inflammation in this model, however, was inhibited by TNF-a neutralization as it was in the subacute DNFB
model. MK2 deficiency also did not show anti-inflammatory effects in acute DNFB-induced contact
hypersensitivity, whereas the p38 inhibitor, SB203580, ameliorated skin inflammation supporting a pathophy-
siological role of p38. When evaluating possible mechanisms, we found that TNF-a production in MK2-deficient
spleen cells was strongly diminished after TLR stimulation but less affected after T-cell receptor stimulation.
Our data suggest that MK2, in contrast to its downstream effector molecule, TNF-a, has a rather elusive role in
T-cell-dependent cutaneous inflammation.
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INTRODUCTION
Mitogen-activated protein kinase (MAPK)-activated protein
kinase 2 (MK2) is one of several kinases that are regulated
exclusively through direct phosphorylation by p38 MAP
kinase in response to stress stimuli (Gaestel, 2006). The role
of the stress-activated p38 MAPK protein kinase cascade in
inflammation was defined several years ago by the anti-
inflammatory effect of the p38 inhibitor, SB203580, and
related compounds (Lee et al., 1994; Jackson et al., 1998).
Accordingly, it was expected that several components of this
kinase cascade may have been essential for early signaling in
the inflammatory response and therefore yielded targets for
anti-inflammatory therapy. Targeted disruption of p38 in
mice results in embryonic lethality and impaired interleukin
(IL)-1 signaling (Allen et al., 2000). Deletion of one of the two
known specific upstream activators of p38, the dual-specific
MAPK kinase 3 (MKK3), leads to a reduction in IL-12
production (Lu et al., 1999) and impaired tumor necrosis
factor (TNF)-alpha-induced cytokine expression (Wysk et al.,
1999), and heterozygosity for p38a reduces ear swelling and
cell infiltration in acute DNFB-induced contact allergy
(Takanami-Ohnishi et al., 2002).
Mice deficient in MK2 showed a reduction in bacterial
lipopolysaccharide (LPS)-induced biosynthesis of TNF-a,
interferon (IFN)-g, IL-1b, IL-6, and nitric oxide, suggesting a
critical role of MK2 in inflammatory cytokine production and
inflammation (Kotlyarov et al., 1999). It was later shown that
MK2 regulates biosynthesis of IL-6 at the levels of mRNA
stability and of TNF-a mainly through an AU-rich element-
dependent translational control (Neininger et al., 2002). The
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crucial role for MK2 in regulating TNF-a and IL-6 production
was also shown in a mouse arthritis model. MK2-deficient
mice had significantly lower LPS-induced TNF-a and IL-6
serum levels when compared with wild-type controls and
were resistant to induction of collagen-induced arthritis
(Hegen et al., 2006). Moreover, deficiency of MK2 has been
shown to markedly reduce infarct size following cerebral
ischemic injury in mice. This protective effect was attributed
to significantly lower expression of IL-1b, but not TNF-a
mRNA (Wang et al., 2002).
A series of pyridinyl imidazole compounds, exemplified
by SB203580, have been developed as specific p38 inhibitors
(Badger et al., 1996). In vivo studies using some of these
compounds have suggested that they might be useful in the
treatment of several inflammatory conditions including
immunologically driven and irritant-associated airway in-
flammation, rheumatoid arthritis, and psoriasis (Badger et al.,
1996; Jackson et al., 1998). However, the preclinical efficacy
of SB203580 has been associated with potential adverse
events (Rogers and Giembycz, 1998; Dambach, 2005), and
targeting p38 directly might thus have liabilities for drug
development. Although p38-deficient mice are lethal, MK2
knockout mice are viable and show a normal phenotype
(Allen et al., 2000).
Taken together, targeting MK2 as a downstream kinase in
the p38 pathway might have advantages over targeting p38
directly. Moreover, in contrast for example to TNF-a, MK2 as
a kinase is considered as a molecular target druggable by
small molecules (Gaestel et al., 2007), an attractive
characteristic that is also reflected by the fact that a number
of pharmaceutical companies are pursuing drug discovery
and development programs with MK2 (Anderson et al., 2007;
Gaestel et al., 2007).
The aim of this study was (i) to determine the biological
role of MK2 in skin inflammation models mainly by
comprehensively comparing wild-type versus knockout mice
responses in several models of cutaneous and systemic
inflammation and (ii) to determine whether MK2 represents
a promising drug target for the treatment of inflammatory skin
diseases.
RESULTS
MK2 is involved in acute, systemic inflammation after
endotoxin challenge in mice
As TNF-a is a key mediator of inflammation and a well-
established drug target in skin inflammation (Schottelius
et al., 2004), we wanted to test the effect of MK2 deficiency
on plasma levels of TNF-a in the model of LPS-induced
systemic inflammation. As expected, homozygous MK2
deficiency resulted in significantly reduced TNF-a serum
levels following a systemic LPS challenge in comparison with
wild-type mice (Po0.05) (Figure 1). Partial deficiency of MK2
(MK2 heterozygous mice) also strongly reduced TNF-a serum
levels, but the reduction did not reach statistical significance.
These data confirm a report published earlier (Kotlyarov
et al., 1999) and show that the MK2-deficient mice we
used for our studies displayed a similar phenotype as
described.
To investigate the pathophysiological role of MK2 in skin
disease, we tested MK2-deficient and wild-type mice in
models of skin inflammation, which display characteristics of
chronic, subacute, and acute skin inflammation.
Impact of MK2 deficiency on the chronic TPA-induced skin
inflammation model in mice
MK2 knockout mice and wild-type controls were subjected
to chronic 12-O-tetradecanoylphorbol-13-acetate (TPA)-in-
duced irritative skin inflammation. Inflammatory edema
formation after repeated TPA exposure was significantly
decreased in MK2-deficient mice on days 5 (Po0.001) and
10 (Po0.05) (Figure 2a). Moreover, a significant reduction of
neutrophil infiltration, as assessed by neutrophil elastase
activity in skin homogenates, could be observed in MK2
knockout versus wild-type mice (Po0.05) (Figure 2c). Over-
all granulocyte infiltration, as assessed by peroxidase activity,
however, was not different in MK2 knockout mice versus
wild-type controls (Figure 2b).
Impact of MK2 deficiency on subacute DNFB- and
DNCB-induced contact allergy models in mice
On repeated challenges with contact allergy-inducing hap-
tens, DNFB (dinitrofluorobenzene)- or DNCB (dinitrochlor-
obenzene)-sensitized mice develop a T-cell-dependent skin
inflammation of a pronounced Th1 phenotype. Owing to the
subacute regimen with repeated challenges, these models
may be particularly relevant for inflammatory skin diseases,
such as psoriasis (Zollner et al., 2004) in which TNF-a protein
expression in lesional skin is suggested to be post-transcrip-
tionally regulated by activated MK2 (Johansen et al., 2006).
First, we tested MK2 knockout mice in a subacute model
of DNFB-induced contact allergy. A significant reduction of
ear edema formation was observed for MK2-deficient mice
compared with the respective wild-type controls with the
strongest reduction seen on day 8 (day 7 Po0.05; day 8
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Figure 1. MK2 deficiency results in suppression of TNF-a production after
systemic LPS exposure. Wild-type, MK2-heterozygous, and MK2-deficient
mice were left untreated (NaCl control) or intraperitoneally challenged with
LPS from E. coli (5mg kg1). TNF-a serum levels as determined by Luminex
measurement were strongly and significantly elevated at 1.5 hours after LPS
challenge in wild-type mice (n¼6), but were completely suppressed in mice
heterozygous for MK2 (n¼ 4) and in MK2-deficient mice (n¼ 3; *Po0.05,
Mann–Whitney U-test).
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Po0.001) (Figure 3a). Interestingly, as in TPA-induced
chronic skin inflammation, the reduction of edema formation
was not accompanied by a consistent reduction in cutaneous
granulocyte infiltration. Peroxidase activity in skin homo-
genates, as a parameter for overall granulocyte infiltration,
was even significantly increased (Po0.05, Figure 3b),
whereas neutrophil elastase activity, as a parameter for
neutrophil infiltration, was significantly decreased (Po0.05,
Figure 3c) in MK2-deficient animals compared with wild-type
controls.
To elucidate whether inflammation in the subacute
DNFB model is driven by TNF-a, we tested TNF-a expression
at the mRNA and protein levels and the effect of neutraliza-
tion with an anti-TNF-a antibody. The TNF-a mRNA levels
were significantly upregulated following repeated challenges
with DNFB in this model peaking at day 8 (Po0.05 day 8 vs
day 5) (Figure 3d, left panel). IL-1b mRNA levels also
increased steadily up to day 8, but the increase was not
statistically significant (Figure 3d, right panel). Neutralization
of TNF-a with two different anti-TNF-a antibodies signifi-
cantly reduced ear edema in this model (Po0.05 for hamster
anti-mouse TNF-a versus hamster control on day 8; Po0.05
for rabbit anti-mouse TNF-a versus rabbit control on days 7
and 8) (Figure 3e) and also strongly and significantly
suppressed protein levels of TNF-a and IL-1b (Po0.01 versus
control for both) (Figure 3f). These data suggest that the
pathophysiology of the subacute DNFB contact allergy model
is mainly driven by the inflammatory effects of TNF-a and
that MK2-deficiency leads to a significant reduction in
ear inflammation, potentially through TNF-a suppression in
this model.
In contrast, the formation of ear edema 8 or 9 days post
challenge was not reduced when MK2 knockout mice were
tested in the subacute DNCB-induced contact allergy model
(Figure 4a). Surprisingly, in this model, the infiltration of
inflammatory cells was even strongly and significantly
increased in MK2-deficient mice compared with wild-type
controls (Po0.001 for cutaneous peroxidase and elastase
activity) (Figure 4b and c). To further investigate whether the
increase of cellular infiltration in MK2-deficient mice in
DNCB-induced contact allergy was accompanied by changes
in cutaneous cytokine production, we analyzed ear homo-
genates of DNCB-challenged mice for the presence of
inflammatory cytokines. TNF-a and IL-1b levels were
increased at 24 hours after the last DNCB challenge in both
MK2 wild-type and deficient mice compared with unchal-
lenged mice (Figure 4d). However, MK2 knockout mice
produced significantly higher levels of TNF-a and IL-1b after
repeated challenges with DNCB when compared with wild-
type controls (Po0.05 for TNF-a, Po0.001 for IL1b).
Increased infiltration of inflammatory cells in MK2 knockout
mice in DNCB-induced contact allergy was thus accompa-
nied by a higher production of TNF-a and IL-1b.
As MK2 deficiency caused different effects on skin
inflammation in DNFB- versus DNCB-induced contact
allergy, we further wanted to elucidate whether TNF-a also
has a pathophysiological role in the subacute DNCB-induced
contact allergy model, that is, whether TNF-a levels are
incrementally increased and whether neutralization of TNF-a
would reduce inflammation equally in this model. In line
with the results from the subacute DNFB model, we observed
increasing TNF-a and IL-1bmRNA expression in the subacute
DNCB model (Po0.05 for TNF-a for days 7 and 9 vs day 6
and for IL-1b for day 9 vs day 6) (Figure 4e). Most importantly,
neutralization of TNF-a with an anti-TNF-a antibody reduced
ear thickness significantly and with comparable efficacy as in
subacute DNFB-induced contact allergy (Figure 3e) in the
subacute DNCB-induced contact allergy (Po0.05 for days 7,
8, and 9) (Figure 4f). Also, in the DNCB-induced contact
allergy model, neutralization of TNF-a strongly and signifi-
cantly suppressed protein levels of TNF-a and IL-1b (Po0.01
for TNF-a and Po0.05 for IL-1b) (Figure 4g).
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Figure 2. Skin inflammation is reduced in MK2-deficient mice in the chronic TPA-induced irritative dermatitis model. MK2-deficient and wild-type mice
(n¼10 per group) were subjected to TPA-induced skin inflammation. Mice ears were treated with TPA on days 1, 3, 5, 8, and 10 and killed on day 10 at 6 hours
after the last TPA application. (a) The kinetics of ear thickness was assessed with a caliper. Skin inflammation was significantly decreased on days 5 and 10 in
MK2-deficient mice compared with wild-type mice (***Po0.001 day 5, *Po0.05 day 10, Mann–Whitney U-test) after sensitization with TPA, whereas skin
inflammation was not significantly decreased on days 3 and 8 in MK2-deficient mice. Moreover, although there was a significant reduction of neutrophil
infiltration as assessed by elastase activity in ear homogenates on day 10 (*Po0.05) (c), peroxidase activity as a parameter for overall granulocyte infiltration was
not significantly different in MK2 knockout mice compared with wild-type controls. (b) DF, dilution factor.
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Taken together, our data establish the central role of
TNF-a in the pathogenesis of both the subacute DNFB- and
DNCB-induced contact allergy models and further show that
the differential functional effects of MK2-deficiency in these
models cannot be explained by the lack of a role for TNF-a in
inducing inflammation in one model versus the other.
Differing effect of MK2 deficiency and p38 inhibition on the
acute DNFB-induced contact allergy model in mice
As MK2 knockout mice showed the most prominent and
significantly reduced ear edema formation in the subacute
DNFB contact allergy model, we wanted to investigate
whether this anti-inflammatory effect of MK2-deficiency
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Figure 3. MK2-deficient mice show decreased skin inflammation in the subacute model of DNFB-induced contact allergy. MK2-deficient and wild-type
mice (n¼ 10 per group) were challenged on the ears with DNFB on days 5, 6, and 7 after sensitization. (a) Ear thickness was measured with a caliper on days 6,
7, and 8 after DNFB sensitization. MK2-deficient mice developed significantly less ear edema when compared with wild-type controls (*Po0.05 day 7;
***Po0.001 day 8, Mann–Whitney U-test). (b, c) Ears were homogenized on day 8 after sensitization and assayed for peroxidase activity as a parameter for
granulocyte infiltration (b) and elastase activity for neutrophil infiltration (c). Both parameters were significantly increased after challenge with DNFB. Although
granulocyte infiltration was significantly increased (*Po0.05), neutrophil infiltration was significantly decreased in MK2-deficient versus wild-type mice
(*Po0.05, Mann–Whitney U-test). The subacute model of DNFB-induced contact allergy is mainly driven by TNF-a. (d) Wild-type mice were challenged with
DNFB on days 5, 6, and 7 after DNFB sensitization. mRNA was extracted from ear homogenates of mice killed on days 5, 6, 7, and 8 after sensitization (n¼ 3 for
each time point). TNF-a and IL-1b mRNA levels steadily increased up to day 8 (*Po0.05 day 8 vs day 5 for TNF-a, Mann–Whitney U-test). (e, f) Treatment with
either hamster or rabbit anti-mouse TNF-a antibodies before challenges (day 5) significantly reduced ear inflammation in subacute DNFB-induced contact
allergy in C57Bl/6 wild-type mice (n¼ 7 for anti-TNF-a antibodies; n¼ 10 for control IgGs). (e) TNF neutralization significantly diminished ear thickness on day
7 (*Po0.05 for rabbit anti-mouse TNF-a versus rabbit control, Mann–Whitney U-test) and on day 8 after sensitization (*Po0.05 for hamster anti-mouse TNF-a
versus hamster control and for rabbit anti-mouse TNF-a versus rabbit control, Mann–Whitney U-test). (f) Neutralization of TNF-a by hamster anti-mouse TNF-a
significantly reduced protein levels of TNF-a and IL-1b (**Po0.01 versus hamster control IgG, Mann–Whitney U-test) in ear homogenates on day 8 after DNFB
sensitization. DF, dilution factor.
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could also be observed in the acute model of DNFB-induced
contact allergy using a single challenge of the same hapten in
sensitized mice. In contrast to the effects seen in the subacute
DNFB-induced contact allergy model after 3 DNFB chal-
lenges, no significant anti-inflammatory effect was seen in
MK2 knockout mice in the acute DNFB contact allergy model
compared with controls (Figure 5a–c). Comparable induction
of ear edema formation (Figure 5a) and granulocyte (Figure
5b) as well as neutrophil infiltration (Figure 5c) was seen in
MK2 knockout and wild-type mice in this model.
To further explore whether the p38 axis has any role in the
pathophysiology of this acute contact allergy model, we
tested the effects of the potent p38 inhibitor, SB203580, in
MK2 wild-type mice compared with the potent glucocorti-
coid, dexamethasone, as a positive control. The pharmaco-
logical inhibition of p38 strongly and dose-dependently
decreased skin inflammation and blocked ear edema forma-
tion and cell infiltration as potently as dexamethasone
(Po0.01 for 0.3 and 1mg kg1 dexamethasone and for 3
and 10mgkg SB203580; inhibition of granulocyte infiltra-
tion: Po0.01 for 1mg kg1 dexamethasone and for 3 and
10mgkg1 SB203580; inhibition of neutrophil infiltration:
Po0.05 for 1mg kg1 dexamethasone and Po0.01 for 3 and
10mgkg1 SB 203580) (Figure 6a–c), showing that the p38
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Figure 4. Skin inflammation is not reduced in MK2-deficient mice in the subacute DNCB-induced contact allergy model. MK2-deficient and wild-type
mice (n¼ 10 per group) were challenged with DNCB on days 6, 7, and 8 after sensitization. (a) Ear thickness was measured with a caliper on days 7, 8, and 9
after DNCB sensitization. No significant differences in ear thickness were detected between MK2-deficient and wild-type mice. (b, c) Ears were homogenized on
day 9 after sensitization and assayed for peroxidase activity as a parameter for granulocyte infiltration (b) and elastase activity for neutrophil infiltration (c).
Both parameters were significantly strongly increased in MK2-deficient compared with wild-type mice (***Po0.001 for granulocyte and neutrophil infiltration,
Mann–Whitney U-test). (d) TNF-a and IL-1b protein levels in ear homogenates were determined on day 9 after sensitization (n¼6–12 for each group).
Both TNF-a and IL-1b were significantly increased in MK2-deficient compared with wild-type mice (*Po0.05 for TNF-a, ***Po0.001 for IL1b). The subacute
model of DNCB-induced contact allergy is driven by TNF-a. (e) Wild-type mice were challenged with DNCB on days 6, 7, and 8 after DNCB sensitization. mRNA
was extracted from ear homogenates of mice killed on days 6, 7, 8, and 9 after sensitization (n¼4 for each time point). TNF-a and IL-1b mRNA levels steadily
increased up to day 9 (*Po0.05 days 7 and 9 vs day 6 for TNF-a and day 9 vs day 6 for IL-1b, Mann–Whitney U-test). (f, g) C57Bl/6 wild-type mice (n¼ 10 for
rabbit anti-TNF-a and n¼ 8 for rabbit IgG controls) were challenged with DNCB on days 6, 7, and 8 after sensitization. Treatment with rabbit anti-mouse
TNF-a antibodies was performed before the challenges (day 6). (f) TNF-a neutralization significantly reduced ear inflammation as assessed by ear thickness
(*Po0.05 versus rabbit IgG control on days 7, 8, and 9, Mann–Whitney U-test). (g) TNF-a neutralization significantly reduced protein levels of TNF-a and
IL-1b (**Po0.01 and *Po0.05 versus rabbit IgG control, respectively, Mann–Whitney U-test) in ear homogenates on day 9 after sensitization. DF, dilution factor.
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axis needs to be intact for inflammation to develop in acute
DNFB-induced contact allergy.
Collectively, these data show that specific MK2 deficiency
does not exert a significant anti-inflammatory effect in this
model of DNFB-induced acute skin inflammation, whereas
the upstream regulatory molecule p38 is clearly involved,
showing the relevance of the p38 pathway in this acute
contact allergy model.
The TNF-a regulatory role of MK2 is consistent for TLR
stimulation but may be restricted in T-cell stimulation
For a better mechanistic understanding of the observed
differential in vivo effects, we further wanted to elucidate the
role of MK2 signaling for the production of TNF-a in the
most prominent pathways in relevant immune cells
ex vivo/in vitro. Stimulation of different toll-like receptors
(TLRs) in splenocytes with their respective ligands led to a
strong induction of TNF-a, which was consistently and
significantly reduced in the absence of MK2 (Po0.01 for
LPS, Po0.05 for zymosan and imiquimod) (Figure 7a). The
LPS in vitro data are consistent with our results observed in
the model of LPS-induced systemic inflammation (Figure 1).
Moreover, in vitro TNF-a production was comparably
inhibited after the pharmacological blockade of p38 in
wild-type splenocytes as in MK2-deficient splenocytes.
Remarkably, a quite similar inhibition of TNF-a produc-
tion was seen in splenocytes stimulated with LPS alone or in
combination with IFN-g or anti-CD40 co-stimulation
(Po0.05 for all stimuli) (Figure 7b, left panel) showing the
robustness of the effects. However, in isolated splenic CD4þ
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(a) As assessed by the ear thickness measurements with a caliper, MK2-deficient and wild-type mice developed similar degrees of ear edema. Moreover, cell
infiltration was not different between MK2-deficient and wild-type mice as determined by peroxidase (b) and elastase (c) activities in ear homogenates as
parameters for granulocyte and neutrophil infiltration, respectively. DF, dilution factor.
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Figure 6. Pharmacological inhibition of p38 strongly and dose-dependently inhibits skin inflammation in the acute DNFB-induced contact allergy model in
wild-type mice. DNFB-sensitized female NMRI mice (n¼10 per group) were s.c. treated with different dosages of the p38 inhibitor, SB 203580, or
vehicle at 2 hours before DNFB challenge on both ears at day 5 after sensitization and killed on day 6. Treatment with the glucocorticoid dexamethasone (Dex)
served as positive control. Both compounds, SB 203580 and dexamethasone, significantly and dose-dependently inhibited (a) ear edema formation as
determined by caliper measurement on day 6 after DNFB sensitization (**Po0.01 for 0.3 & 1mg kg1 dexamethasone and for 3 and 10mg kg1 SB203580,
Mann–Whitney U-test) as well as (b) granulocyte infiltration (peroxidase activity) (**Po0.01 for 1mg kg1 dexamethasone and for 3 and 10mg kg1 SB203580,
Mann–Whitney U-test) and (c) neutrophil infiltration (elastase activity in ear homogenates) (*Po0.05 for 1mg kg1 dexamethasone and **Po0.01 for
3 and 10mg kg1 SB 203580, Mann–Whitney U-test). DF, dilution factor.
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T cells stimulated with anti-CD3/anti-CD28 antibodies, MK2
deficiency did not significantly alter the production of TNF-a
(Figure 7b, right panel).
In summary, these in vitro data show that the p38/MK2
axis has a pivotal role in TLR-stimulated production of TNF-a
in splenocytes, whereas anti-CD3/anti-CD28-driven TNF-a
production in splenic T cells appears to be less dependent on
MK2 signaling.
DISCUSSION
The p38 MAP kinase pathway has been shown to be a central
regulator of inflammation (Lee et al., 1994). MK2 is
exclusively regulated by p38 and controls key inflammatory
cytokines such as TNF-a and IL-6 (Kotlyarov et al., 1999;
Neininger et al., 2002) as well as chemokines and adhesion
molecules (Gorska et al., 2007). Both kinases have thus been
identified as potentially promising drug targets and have
become the focus of several drug discovery programs
(Gaestel, 2006; Duraisamy et al., 2008). Targeting MK2 as
a downstream kinase in the p38 pathway might have
advantages over targeting p38 directly, because pharmaco-
logical inhibition of p38 was implicated with potential
adverse events (Dambach, 2005). The relevance of MK2 as
a drug target was elucidated for certain inflammatory diseases
such as rheumatoid arthritis in relevant animal models
(Hegen et al., 2006); however, its target relevance in
inflammatory skin disease has remained elusive. Although a
recent report shows a role of MK2 in the oxazolone-induced
contact allergy model (Funding et al. 2009), here, we provide
a comprehensive characterization of the pathophysiological
role of MK2 in a broad panel of murine models of skin
inflammation, contributing to its evaluation as a drug target in
inflammatory skin disease.
Here, we show that MK2 deficiency exerts anti-inflamma-
tory effects in chronic TPA-induced irritative skin inflamma-
tion and in the subacute model of DNFB-induced contact
allergy leading to a significant reduction in the development
of ear edema (Figures 2a and 3a). However, the reduction in
edema formation was accompanied by an only partial
reduction of inflammatory cell infiltration parameters in
these models. Although neutrophil infiltration, assessed by
elastase activity, was significantly reduced in MK2-deficient
mice (Figures 2c and 3c), general granulocyte infiltration, as
assessed by cutaneous peroxidase activity, was in tendency
or significantly enhanced (Figures 2b and 3b, respectively).
Moreover, we did not observe any inhibitory effect of MK2
deficiency on inflammation in the subacute DNCB contact
allergy model. Here, a lack of significant inhibition of ear
edema formation was accompanied by even significantly
increased cell infiltration parameters (Figure 4a–c). It is noted
that this increase in cutaneous cell infiltration in MK2
knockout mice was also accompanied by a significant
increase in TNF-a and IL-1b production in the inflammatory
skin lesions of MK2-deficient mice compared with wild-type
controls (Figure 4d). This result was surprising, because
experiments with MK2 knockout mice used in our studies
were able to confirm that LPS-induced plasma levels of
TNF-a were drastically reduced as reported earlier (Figure 1)
(Kotlyarov et al., 1999).
Remarkably, the differential effects of MK2 deficiency in
the subacute DNFB- versus the subacute DNCB-induced
contact allergy model cannot be explained by a different role
for TNF-a in the pathogenesis of these models, because in
both models cutaneous TNF-a expression significantly
increased with inflammation (Figures 3d and 4e) and
neutralization of TNF-a exerted a potent and comparable
anti-inflammatory effect (Figures 3e and 4f). Although both
DNFB and DNCB are considered Th1-inducing haptens, a
variety of studies have shown a number of differences in the
cellular and molecular mechanisms elicited by these
compounds, all of which may have contributed to the
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Figure 7. (a) TNF-a secretion after stimulation with different TLR stimuli is
MK2-dependent. Spleen cells (5 106ml1) from C57Bl/6 mice (wt; dark gray
bars) or MK2-deficient mice (white bars) were stimulated for 4 hours with
several TLR stimuli (LPS at 5 mgml1, zymosan at 10 mgml1, imiquimod at
1mgml1, or CpG ODNs at 10 mgml1) as indicated. As a control, wild-type
spleen cells were also stimulated in the presence of the p38 MAP kinase
inhibitor, SB203580, at 10 mM (light gray bars). TNF-a content in supernatants
was determined by ELISA. Absolute values are depicted from two (CpG) or
3–6 (all others) mice as means with error bars indicating SD. Significant
differences between cell cultures from wild-type and MK2-deficient mice
were determined by the Mann–Whitney U-test (*Po0.05, **Po0.01). (b) MK2
deficiency significantly diminishes TNF-a secretion after LPS stimulation with
and without co-stimuli, but not after TCR stimulation. Splenocytes from
C57Bl/6 (dark gray bars) and MK2-deficient mice (white bars) were left
untreated or activated with LPS alone or in combination with co-stimulation
(IFN-g or anti-CD40) for 4 hours (left panel). As a control, wild-type spleen
cells were also stimulated in the presence of the p38 MAP kinase inhibitor,
SB220025, at 10mM (light gray bars). TNF-a levels in supernatants were
analyzed by ELISA, and the results are shown as the means from four mice
(±SD). CD4þ T cells separated from the spleens of either C57Bl/6- (dark gray
bars) or MK2-deficient mice (white bars) were activated with plate-bound
anti-CD3 and anti-CD28 antibodies for 72 hours (right panel). As a control,
wild-type CD4þ T cells were also stimulated in the presence of the p38 MAP
kinase inhibitor, SB220025, at 10 mM (light gray bars). TNF-a levels in
supernatants were analyzed by ELISA. Results are shown as the means from
four mice (±SD). Significant differences between cell cultures from wild-type
and MK2-deficient mice were determined by Mann–Whitney U-test
(*Po0.05).
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differential effects observed in contact allergy in mice in the
absence of MK2, namely the different effects on CD86 and
HLA-DR expression in dendritic cells (Manome et al., 1999)
indicating a more potent role of DNCB over DNFB in
dendritic cells and the distinct ability of DNFB to induce
IL-10-producing mast cells and NK cell-mediated memory
responses (O’Leary et al., 2006; Grimbaldeston et al., 2007)
where the p38/MK2 pathway may have a differential role
versus contact allergy elicited by DNCB.
When tested in the acute model of DNFB-induced contact
allergy, MK2 knockout mice did not develop significantly less
skin inflammation than their wild-type controls (Figure 5a–c).
In contrast, the pharmacological inhibition of p38 potently
and dose-dependently abrogated both edema formation and
infiltration of inflammatory cells in acute DNFB-induced
contact allergy (Figure 6a–c). These results confirm the
reported role of p38 MAP kinase in the pathophysiology of
acute DNFB-induced contact hypersensitivity (Takanami-
Ohnishi et al., 2002). The lack of a significant anti-
inflammatory effect by MK2 deficiency in acute DNFB-
induced contact allergy thus cannot be attributed to a lesser
pathophysiological role of the p38 pathway in this skin
inflammation model. The p38 kinase has also been shown to
be activated in lesional psoriatic skin (Johansen et al., 2005),
supporting its relevance in human inflammatory skin disease.
One possible explanation for the inconsistent impact of
MK2 deficiency in T-cell-dependent contact allergy models
might be provided by the results of our mechanistic studies in
mouse splenocytes. We show that, as in vivo, MK2 has a
pivotal role in TLR-triggered TNF-a production in spleno-
cytes. In contrast, however, the CD3/CD28-mediated TNF-a
production in splenic T cells appears to be less dependent on
MK2 signaling.
The fact that TLR-dependent, but not TCR-dependent,
TNF production is significantly decreased in MK2-deficient
and SB22025-treated splenocytes is in agreement with the
established role of the p38/MK2 module in signal transduc-
tion located directly downstream to the canonical
TLR4/IRAK4/TAK1/MKK3/6 pathway (summarized in Gaestel,
Kotlyarov, and Kracht, 2009). In contrast, stimulation of
TNF-a production in response to TCR stimulation could
proceed in a non-canonical manner through non-receptor
protein tyrosine kinases, such as Lck (Salvador et al.,
2005), Itk, or Syk, in a more p38/MK2-independent manner.
This non-canonical stimulation of TNF-a generation down-
stream of TCR stimulation could in turn explain that the
pharmacological blockade of p38 by the compound
SB220025 and MK2 deficiency shows much lesser effects
on TNF production in splenocytes on anti-CD3/anti-CD28
stimulation.
One could further hypothesize that the autoimmune
suppressor Gadd45a may have some function in the
differentiated role of TCR-mediated TNF production in
splenocytes. Gadd45a can inhibit p38 Tyr323 phosphoryla-
tion, which is specific for the non-canonical or alternative
pathway of p38 activation in T cells (Salvador et al., 2005).
Taken together, our results confirm the crucial function of
MK2 in LPS-induced TNF-a production in systemic inflam-
mation and further support the observation that this axis has
distinct roles for different inflammatory pathways in different
cell types and target organs.
Here, we show that MK2 deficiency exerts limited anti-
inflammatory effects or can even enhance inflammation in
specific, more chronic mouse models of skin inflammation in
which TNF-a has a central role in the development of
disease, and, in contrast to p38 inhibition, did not exert
inhibitory effects in an acute T-cell-dependent DNFB-
induced contact allergy model. These results may indicate
that MK2 is bypassed in skin inflammation or that MK2
function is compensated for by a different kinase. One such
kinase candidate may be MK3, another MAPKAP kinase
downstream of p38, which has been described to be also
involved in TNF-a production and which might compensate
for the function of MK2 (Hegen et al., 2006; Ronkina et al.,
2007).
Our results are in partial contrast to other reports that
concluded a general potent anti-inflammatory effect of MK2
inhibition, based on MK2 deficiency in other cytokine-driven
diseases such as LPS-induced systemic inflammation or
mouse arthritis models (Kotlyarov et al., 1999; Hegen et al.,
2006) and also on a recent report showing that MK2
deficiency diminishes inflammation in an oxazolone-induced
acute allergic contact dermatitis model (Funding et al. 2009).
Interestingly, MK2 deficiency has been shown to exacerbate
TNF-dependent inflammatory bowel disease in the mouse
(Kontoyiannis et al., 2002). The observed differences may be
based on the distinct role for the p38/MK2/TNF-a axis in the
pathogenesis of these different inflammation models in
different target organs.
From a methodological point of view, our data show that
drawing general conclusions from a single skin inflammation
model alone may not be reliable. The data we obtained in the
subacute DNFB-induced contact allergy (and also the chronic
TPA-induced irritative skin inflammation model), suggesting
an impact of MK2 in skin inflammation, were neither
confirmed in a different subacute contact allergy model nor
in the acute DNFB model, when the hapten was applied in a
more acute setting. Therefore, both the kinetics of the model
(acute versus subacute) and the resulting dominating stimu-
latory pathways (for example, TCR stimulation versus
cytokine stimulation) as well as the choice of hapten (DNFB
versus DCNB) appear to have an impact on the biological
role of MK2 in skin inflammation and its downstream effects
on TNF-a. Investigating the effects of compounds or genetic
alterations in several different contact allergy models
comprehensively may thus be required before general
conclusions can be drawn from a data set.
In conclusion, our studies confirm the role of MK2 in an
acute TLR-driven systemic inflammation, whereas MK2
seems to have at least a less prominent and more complex
role in skin inflammation. However, the entire role of MK2 in
chronic relapsing T-cell-dependent skin diseases in man is
still not fully understood and awaits further analysis. As
expression analysis of MK2 in human lesional skin from
patients with chronic plaque-type psoriasis revealed an
activation of MK2 protein in inflamed psoriatic skin (Johansen
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et al., 2006), the role of MK2, for example, in psoriasis, is still
subject to further investigations.
As neutralization or inhibition of TNF-a has been validated
as a potent therapy for rheumatoid arthritis, inflammatory
bowel disease, and psoriasis in the clinic (Schottelius et al.,
2004), disruption or dampening of TNF-a production would
be expected to yield good therapeutic effects. It would thus
seem conceivable that MK2 is an attractive target for a
pharmacological inhibition in treating a variety of inflamma-
tory diseases. With the data available to date, including our
findings reported here, this approach might yield more
therapeutic promise in rheumatoid arthritis than in inflam-
matory skin diseases such as psoriasis or atopic dermatitis.
Future studies with MK2-deficient mice in other animal
models of disease may be able to further elucidate the role of
MK2 for other inflammatory conditions such as Crohn’s
disease or ulcerative colitis.
MATERIALS AND METHODS
Mice
C57Bl/6 mice (purchased from Charles River, Sulzfeld, Germany),
NMRI female mice (from ‘‘Schoenwalde NMRI colonies’’ exclusively
bred for Bayer Schering Pharma AG at Charles River, Germany), and
MK2 knockout mice (provided from Hannover Medical School,
Hannover, Germany) in the age group of 8–12 weeks were housed in
the animal facility at the Bayer Schering Pharma AG. All animal
studies were approved by the competent authority for labor
protection, occupational health, and technical safety for the state
and city of Berlin, Germany, and were performed in accordance with
the ethical guidelines of Bayer Schering Pharma AG.
Systemic endotoxin-induced inflammation in mice
C57Bl/6 wild-type, MK2-heterozygous, and MK2-deficient mice were
treated by intraperitoneal injection with 5mgkg1 LPS (E. coli 0111:B4;
Sigma L-4391, Steinheim, Germany) or NaCl control. At 1.5hours after
LPS challenge, the mice were killed, and the serum levels of TNF-awere
determined by Luminex assay (Biorad, Munich, Germany).
Acute DNFB-induced contact allergy model
For sensitization, female WT and MK2-deficient mice were topically
treated on day 0 and day 1 with 25ml of 0.5% (w/v) 2,4-
dinitrofluorobenzene (DNFB) (Sigma) in acetone/olive oil 4:1 (v/v)
on the shaved abdomen. After 5 days, groups of 10 mice were
challenged by the topical application of 20 ml of 0.3% (w/v) DNFB in
acetone/olive oil 4:1 (v/v) on both sides of one ear. Small molecule
inhibitors were applied subcutaneously (s.c.) in a volume of 0.1ml
per 20 g body weight in 0.9% NaCl solution containing 0.085% Myrj
53 (ICI, UK) and 5% ethanol 2 hours before DNFB challenge of the
animals on day 5. On day 6 (24 hours after challenging animals), the
thickness of the inflamed ears were determined, and myeloperox-
idase (for granulocyte infiltration) and granulocyte elastase activities
(a parameter for neutrophil infiltration) were measured in homo-
genates of inflamed ears as described earlier (Schottelius et al., 2002;
Zugel et al., 2002).
Subacute DNFB- and DNCB-induced contact allergy models
To examine the role of MK2 in the subacute DNFB model, female
and male WT and MK2 knockout mice were topically sensitized on
day 0 and day 1 with 25 ml of a 0.5% (w/v) DNFB (Sigma) solution in
acetone/olive oil 4:1 (w/v) on the shaved abdomen. On days 5, 6,
and 7, contact allergy was induced by repeated challenge of the ears
with topically applied DNFB (10 ml of a 0.15% [w/v] DNFB solution
in acetone/olive oil 4:1 [w/v]). Ear thickness was monitored during
the study as follows: day 0, day 5 (before challenge), day 6 (24 hours
after first challenge), day 7 (24 hours after second challenge), and
day 8 (24 hours after third challenge). In the subacute DNCB model,
female and male WT and MK2 knockout mice were topically
sensitized on day 0 with 25 ml of a 0.5% (w/v) 2,4-dinitrochlor-
obenzene (DNCB) (Merck, Darmstadt, Germany) in acetone/olive oil
4:1 (w/v) on the shaved abdomen. On days 6, 7, and 8, contact
allergy was induced by repeated challenge of the ears with topically
applied DNCB (10 ml of a 0.15% [w/v] DNCB solution in acetone/
olive oil 4:1 [w/v]). Ear thickness was monitored during the study as
follows: day 0, day 6 (before challenge), day 7 (24 hours after first
challenge), day 8 (24 hours after second challenge), and day 9
(24 hours after third challenge). On day 8 (DNFB) or day 9 (DNCB),
animals were killed, and peroxidase activity (for granulocyte
infiltration) and elastase activity (a parameter for neutrophil
infiltration) were measured in homogenates of inflamed ears as
described earlier (Schottelius et al., 2002; Zugel et al., 2002).
Genders have been combined in all figures as no significant gender
differences have been observed for any of the skin inflammation
models investigated.
TNF-a neutralization in subacute DNFB- and DNCB-induced
contact allergy
Female C57Bl/6 mice were sensitized with 25ml of 1% DNCB in
acetone/olive oil (4:1) on the shaved flank skin on day 0. Challenges
with 10ml 1% DNCB in acetone/olive oil (1:9) on the dorsum of both
ears were performed on days 6, 7, and 8. As treatment in both contact
allergy models purified rabbit polyclonal anti-mouse-TNF-a antibodies
(endogen) and in an additional treatment group in the subacute DNFB
model purified hamster polyclonal anti-mouse TNF-a (Abcam
Cambridge, UK) and as isotype controls purified rabbit and purified
hamster IgG (AbD Serotec, Munich, Germany) was used.
The proteins were prepared for in vivo use with SLIDE-A-LYZER
dialysis cassettes (Serotec). Treatment was applied 1 hour before the
first challenge i.p. Ear thickness was determined over the time course
with a custom-built automated caliper/micrometer (Bayer Schering
Pharma AG, Berlin, Germany). At day 9, animals were killed and the
ears were cut, weighed, and mechanically homogenized in 2ml
homogenization buffer (hexadecyltrimethylic ammonium bromide/
morpholinopropan sulfonic acid (Sigma)), centrifuged at 25,000 g for
20minutes at 121C, and the supernatant was used for determination
of immune mediators. Cutaneous granulocyte infiltration was
assessed by myeloperoxidase activity assay in ear homogenates as
described earlier (Schottelius et al., 2002). Cytokine levels in ear
homogenates were measured using MSD 96-Well MULTY-ARRAY
and MULTI-SPOT technology (Meso Scale Discovery, Gaithersburg,
MD) according to the manufacturer’s instructions.
Chronic TPA-induced skin inflammation model
Ten microliters of the phorbol ester TPA (0.01 w/v) were applied to
the inner and outer surfaces of each mouse ear using a micropipette.
TPA was applied over a 10-day course on alternate days (days 1, 3,
5, 8, and 10). Ear thickness was assessed with a caliper starting
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6hours after TPA application (Alford et al., 1992). Animals were
killed on day 10 at 6 hours after last TPA application, and their ears
were cut off, snap frozen, and later analyzed for peroxidase and
elastase activity as described above.
Determination of elastase and peroxidase activities in ear
homogenates
Peroxidase activity assay. Peroxidase activity as a measure of total
granulocyte infiltration was measured as described earlier (Schottelius
et al., 2002). Briefly, tetramethylbenzidine (TMB) dihydrochloride was
used as a sensitive chromogenic substrate for peroxidase. To convert
TMB into TMB dihydrochloride, 34ml of 3.7% hydrochloric acid
(equimolar) was added to 5mg of TMB. Then, 1ml of DMSO was
added. This stock solution was slowly added to sodium acetate–citric
acid buffer (0.1mol l1, pH 6.0) in a ratio of 1:100. Two hundred
microliters of this TMB solution, 40ml of the homogenized sample, and
25ml of 1mM H2O2 were added to a microtiter plate to start the
reaction. The reaction was stopped after 30minutes with 45ml of 1N
H2SO4. Changes in OD were monitored at 450nm at 251C against the
mixture of all solutions without the added sample homogenate.
Absolute extinction numbers multiplied by respective dilution factors
were used to express peroxidase activity.
Elastase activity assay. Elastase activity was measured by
fluorescence of 7-amino-4-methyl-coumarin (AMC) that is released
from the substrate MeO-Succ-Ala-Ala-Pro-Val-AMC (Bachem, Tor-
rance, CA). Homogenized samples in HTAB were diluted 1/10 in
cetrimide buffer (0.3% cetrimide, 0.1 M Tris, and 1M NaCl, pH 8.5).
The substrate MeO-Succ-Ala-Ala-Pro-Val-AMC (300mM in DMSO)
was diluted 1/100 in cetrimide buffer to a working concentration of
3mM. In cetrimide buffer, diluted samples were pipetted in multiwell
plates, and the reaction was started by addition of the AMC substrate
at 37 1C. The reaction was stopped after 1 hour with ice-cold 100mM
Na2CO3, and samples were measured in a Spectra Max Gemine
(Molecular Devices, Menlo Park, CA) at 380 nm and compared
against a standard curve with the AMC standard 7-amino-4-
methylcoumarin (5mM in ethanol).
Cytokine analyses in serum from LPS-triggered systemic
inflammation model and in ear homogenates from skin
inflammation models
Inflamed ears from mouse skin inflammation models were mechani-
cally homogenized in 2ml homogenization buffer (hexadecyltri-
methylic ammonium bromide/morpholinopropan sulfonic acid,
Sigma, Deisenhofen, Germany), centrifuged at 25,000g for 20minutes
at 12 1C, and supernatants were used for determination of immune
mediators. Cytokine levels in ear homogenates were determined using
a multiplex chemiluminescence method and MesoScale SI 6000
equipment (MesoScale Discovery, Gaithersburg, MD).
Gene expression analyses in mouse skin
For purification of RNA from mouse skin, ears were homogenized in
800ml lysis buffer and digested with 2mgml1 Proteinase K (BD
Biosciences, Erembodegem, Belgium) for 1 hour. Purified RNA from
mouse skin was qualified with the Agilent Bioanalyzer 2100 system
with RNA 6000 Nano Assay Kit (Agilent Technologies, Santa Clara,
CA). cDNA was synthesized using Reverse Transcription Reagents
and GeneAmp PCR System 9700 (Applied Biosystems, Foster City,
CA). RT-PCR was performed in 12.5ml using a universal PCR Master
Mix without UNG (Eurogentec, Cologne, Germany) on a 7900 HT
Sequence Detection System (Applied Biosystems) under thermal
conditions: 40 cycles at 951C for 10minutes, 951C for 15 seconds,
and 601C for 1minute. Expression of target genes was quantified as
the fold expression of the housekeeping gene, hypoxanthine
phosphoribosyltransferase (HPRT). The expression of the following
mouse genes was determined in triplicated analyses using Assays on
demand from Applied Biosystems: IL-1b (Mm 00434228_m1) and
TNF-a (Mm 00443258_m1).
Cell culture
Spleen cells from C57Bl/6 wild-type or Mapkapk2tm1Mgl (C57Bl/6) mice
were brought into suspension after squeezing through a cell strainer in
RPMI-1640 and supplemented with 10% FCS, 1mM L-glutamine,
100Uml1 penicillin, and 100mgml1 streptomycin at a density of
5 106 cells per ml. For TLR stimulation, cells were then directly
stimulated for 4hours with either 5mgml1 LPS (TLR4 grade, Alexis,
Lo¨rrach, Germany) alone or in combination with co-stimulation: either
10ngml1 of IFN-g (R&D Systems, Wiesbaden, Germany) or activating
anti-CD40 antibody (clone 3/23, 1mgml1; BD Bioscience, Heidelberg,
Germany). Furthermore, splenocytes were stimulated for 4hours with
other TLR stimuli such as 10mgml1 zymosan (Sigma, Steinheim,
Germany), 1mgml1 imiquimod (Sequoia Research Product, Reading,
UK), or 10mgml1 CpG ODN (R&D Systems, Germany). As a control,
wild-type spleen cells were treated additionally with p38 MAP kinase
inhibitors SB203580 (10mM; Merck Biosciences, Darmstadt, Germany)
or SB220025 (10mM; Axxora, Lo¨rrach, Germany), respectively.
For TCR stimulation, CD4þ T cells were positively separated
from splenocytes by using anti-CD4 (L3T4)-coated magnetic MACS
beads (Miltenyi Biotech, Bergisch Gladbach, Germany) following
the manufacturer’s protocol. T cells were cultured at a density of
2 106 cells per ml in RPMI-1640 medium supplemented with FCS
(10% v/v), L-glutamine (2mM), and penicillin/streptomycin (each at
10,000Uml1) (all Biochrom KG, Berlin, Germany) and stimulated
with plate-bound anti-CD3 (clone 17A2, 10 mgml1; BD Bioscience)
and anti-CD28 (clone 37.51, 10 mgml1; BD Bioscience). As a
control, wild-type spleen cells were treated additionally with
SB203580 (Merck Biosciences) at a concentration of 10 mM.
Supernatants were collected after stimulation of the respective
cells and cytokine concentrations were determined with TNF-a
ELISA (OptEIA set; BD Biosciences) according to the manufacturer’s
description.
Statistical methods
Statistical methods used for murine skin inflammation models
(comparison of groups in kinetic measurements of skin thickness)
were the Kruskal–Wallis and Mann–Whitney U-tests by SPSS
software (SPSS). Statistics for end point parameters were collected
by Fieller’s test using a program from Bayer Schering Pharma AG
based on the SAS System for Windows 6.12 (SAS Institute)
(Schottelius et al., 2002). Statistical methods used for ex vivo and
in vitro investigations were the Mann–Whitney U-test and Wilcox-
on’s matched-pairs signed-ranks test, respectively, using SPSS
software. If not otherwise indicated, mean values±SD are shown.
Statistical significances at Po0.05, o0.01, and o0.001 are
indicated by one, two, and three asterisks, respectively.
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